2-trifluoromethanesulfonyloxy-7,7-dimethylbicyclo[3.1.1]hept-2-ene | 42108-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-trifluoromethanesulfonyloxy-7,7-dimethylbicyclo[3.1.1]hept-2-ene
• 英文别名: 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl triflate；6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl trifluoromethanesulfonate；6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl trifluoromethanesulfonate；6,6-Dimethyl-2-norpinen-2-yltrifluormethansulfonat；Nopinyl-triflat；Nopinyltriflat；(6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl) trifluoromethanesulfonate
• CAS: 42108-83-8
• 化学式: C₁₀H₁₃F₃O₃S
• 分子量: 270.273
• InChiKey: BLXQGUZXEPRLEV-UHFFFAOYSA-N

物化性质

• 沸点：
  277.3±40.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-trifluoromethanesulfonyloxy-7,7-dimethylbicyclo[3.1.1]hept-2-ene 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 二乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 32.0h， 生成 1-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)-buta-1,3-dien-2-methanol
  参考文献：
  名称：

  通过镁碳金属化-6-π-电环化方案对环状酮进行芳基环化。

  摘要：

  描述了环酮芳基环化的新策略。炔丙醇与酮的三氟甲磺酸酯的钯（0）偶联以及乙烯基氯化镁的添加生成三烯作为镁螯合物，可以用亲电子体将其淬灭。在某些情况下，三烯在反应条件下环化。芳香化是通过暴露于二氧化锰或二氯二氰基醌（DDQ）来完成的。[反应：看文字]

  DOI：

  10.1021/ol047602y
• 作为产物：
  描述：

  三氟甲基磺酰氟 、 6,6-二甲基二环[3.1.1]庚烷-2-酮 生成 2-trifluoromethanesulfonyloxy-7,7-dimethylbicyclo[3.1.1]hept-2-ene
  参考文献：
  名称：

  Vinyl Cations; 11¹. Improved Synthesis of Nonafluorobutanesulfonates (Nonaflates)

  摘要：

  DOI：

  10.1055/s-1973-22191

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Ding Hong

  公开号：US20110237553A1

  公开（公告）日：2011-09-29

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• Chiral ligands and their transition metal complexes
  申请人：Scholz Ulrich

  公开号：US20070066825A1

  公开（公告）日：2007-03-22

  The present invention relates to chiral phosphorus compounds and their transition metal complexes, and also to the use of these transition metal complexes, especially in asymmetric syntheses.

  本发明涉及手性磷化合物及其过渡金属配合物，以及这些过渡金属配合物的应用，特别是在不对称合成中的应用。
• Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
  申请人：Wyeth

  公开号：US20020198196A1

  公开（公告）日：2002-12-26

  The present invention provides novel tricyclic diazepine compounds and methods and pharmaceutical compositions utilizing them for the treating or preventing disorders including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, congestive heart failure or for inducing temporary delay of urination, and in conditions with increased vascular resistance and coronary vasoconstriction; and for the treating or preventing disorders remedied or alleviated by oxytocin antagonist activity, including suppression of preterm labor, dysmenorrhea, endometritis, and for suppressing labor at term prior to caesarean delivery. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.

  本发明提供了新颖的三环二氮杂环烷化合物，以及利用它们用于治疗或预防包括尿崩症、夜尿症、夜尿频、尿失禁、出血和凝血障碍、充血性心力衰竭或暂时延迟排尿、以及在血管阻力增加和冠状血管收缩的情况下；以及用于治疗或预防通过催产素拮抗活性得到缓解或减轻的疾病，包括抑制早产、痛经、子宫内膜炎，以及在剖宫产前抑制分娩。这些化合物还可用于提高农场动物的生育率、生存率和同步动情期；以及治疗中枢神经系统中催产素系统功能障碍，包括强迫症（OCD）和神经精神障碍。
• Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
  申请人：Wyeth

  公开号：US07022699B2

  公开（公告）日：2006-04-04

  The present invention provides novel tricyclic diazepine compounds and methods and pharmaceutical compositions utilizing them for the treating or preventing disorders including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, congestive heart failure or for inducing temporary delay of urination, and in conditions with increased vascular resistance and coronary vasoconstriction; and for the treating or preventing disorders remedied or alleviated by oxytocin antagonist activity, including suppression of preterm labor, dysmenorrhea, endometritis, and for suppressing labor at term prior to caesarean delivery. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.

  本发明提供了新型三环二氮平化合物，以及利用它们治疗或预防疾病的方法和制药组合物，包括尿崩症、夜间遗尿、夜尿症、尿失禁、出血和凝血障碍、充血性心力衰竭或诱导暂时延迟排尿，并且在增加血管阻力和冠状动脉收缩的情况下；并用于治疗或预防通过催产素拮抗剂活性缓解的疾病，包括抑制早产、痛经、子宫内膜炎和在剖腹产前抑制足月分娩。这些化合物还可用于提高农业动物的生育率、生存率和同步发情；以及治疗中枢神经系统中催产素系统的功能障碍，包括强迫症和神经精神障碍。
• Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
  申请人：Abbvie Inc.

  公开号：EP2757105A1

  公开（公告）日：2014-07-23

  This invention pertains to compounds, or therapeutically acceptable salts thereof, which inhibit the activity of Bcl-2 anti-apoptotic proteins, pharmaceutical compositions containing the compounds, and compounds and compositions for use in treating diseases during which anti-apoptotic Bcl-2 proteins are expressed.

  本发明涉及抑制 Bcl-2 抗凋亡蛋白活性的化合物或其治疗上可接受的盐类、含有这些化合物的药物组合物，以及用于治疗表达抗凋亡 Bcl-2 蛋白的疾病的化合物和组合物。